Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 36

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 36
---
 a commercial market;                                                          |

| • | set a commercially viable price; |

| • | obtain commercial qualities of the products at acceptable cost levels; |

| • | develop and maintain a commercial organization capable of sales, marketing and distribution in the markets 
 where the product is to be sold; and                                                                       |

| • | obtain adequate reimbursement from third parties, including government, departments and healthcare payors. |

In addition, because of the
numerous risks and uncertainties associated with product development, including that our product candidates may not advance through development
or achieve the endpoints of applicable clinical trials, we are unable to predict the timing or amount of increased expenses, or when or
if we will be able to achieve or maintain profitability. Even if we are able to complete the process described above, we anticipate incurring
significant costs.

Even if we are able to generate
royalty and/or milestone revenues from the sale of product candidates, we may not become profitable and may need to obtain additional
funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we
may be unable to continue our operations at planned levels and may be forced to cease or reduce our operations.

| 18 |

There can be no assurance
that we will operate profitably, produce a reasonable return, if any, on investment, or remain solvent. If our strategy proves unsuccessful,
stockholders could lose all or part of their investment.

If we require or seek to raise additional capital to fund our operations and we fail to obtain necessary financing, we may be unable to complete the development of our product candidates.

We expect to continue to spend
substantial amounts of our cash resources going forward in order to advance the development of our product candidates. We believe we have
sufficient funds to continue our operations into the first quarter of 2025, and we believe that we will need to raise additional capital
to fund our operations thereafter.

Until such time as we can
generate a sufficient amount of revenue from the product candidates we license, if ever, we expect that we may finance future cash needs
through, among other things, public or private equity or debt offerings. Such offerings may take place in the United Kingdom, the United
States or other foreign countries. However, if we are unable to raise capital when needed, or on terms acceptable to us, our business
could be significantly harmed. If we raise additional funds through the issuance of debt or additional equity securities, such issuance
could result in dilution